COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced that three abstracts describing the science and initial clinical evaluation of Grafix, a cellular wound care dressing, in the limb salvage and recalcitrant wound setting were accepted for presentation at the 24th Annual Symposium on Advanced Wound Care and Wound Healing Society. The abstract, “Characterization of novel human mesenchymal stem cell-containing skin substitutes for the treatment of wounds” by lead author Dr. Dana Yoo, was awarded the top score of all entries to the meeting as determined by a blinded review panel that evaluated submissions for their importance and relevance to the field of wound care research. Dr. Yoo will give a podium presentation on the subject in Session 41.1 on April 16.
Grafix is a living skin substitute comprised of a biologic membrane containing endogenous mesenchymal stem cells (MSCs) that is used to promote healing in chronic wounds, limb salvage procedures, and burns. Studies have demonstrated that Grafix contains the necessary components for optimal dermal repair including sustained expression of an array of growth factors and cytokines that limit inflammation and promote each phase of wound healing.
“Chronic wounds remain a debilitating and at times life-threatening problem for over 5 million people in the United States alone,” said Walter A. Conlan III, M.D., CWS, Medical Director of the Wound Healing Center at Osceola Regional Medical Center and Grafix investigator. “Research has shown that stem cells have the unique ability to provide trophic support and control unwanted inflammation, making them an ideal candidate in the chronic wound setting. At our center, we were able to safely close chronic wounds with Grafix that were otherwise unresponsive to advanced therapies. Grafix should be considered in the management of patients with chronic wounds that are non-responsive to conventional treatment.”
On April 16 (Session 41.2) Dr. Conlan will give a podium presentation entitled, “The use of a novel, human mesenchymal stem cell-containing skin substitute in the treatment of refractory wounds: a case series,” describing the performance of the product in patients with difficult to treat wounds that have failed at least one advanced therapy.
The abstract entitled, “Limb salvage utilizing a human mesenchymal stem cell-containing skin substitute: results of a case series in patients with diabetic foot ulcers” will also be presented in the poster session on April 15. This study demonstrated the utility of Grafix as a salvage treatment in patients with severe wounds who were at risk for amputation from diabetic foot ulcers.
While at SAWC visit Osiris at booth 938.
About Osiris Therapeutics
Osiris Therapeutics, Inc. is the leading stem cell company focused on developing products to treat serious medical conditions in the inflammatory, autoimmune, orthopedic, wound care and cardiovascular areas. The company's pipeline of internally developed biologic drug candidates under evaluation includes Prochymal for inflammatory, autoimmune and cardiovascular indications, as well as Chondrogen for arthritis in the knee. Osiris is a fully integrated company, with capabilities in research, development, manufacturing and distribution of stem cell products. Osiris has developed an extensive intellectual property portfolio to protect the company's technology, including 47 U.S. and over 300 foreign patents. Osiris and Prochymal are registered trademarks of Osiris Therapeutics, Inc. More information can be found on the company's website, www.Osiris.com. (OSIR-G)
Osiris and Genzyme formed a strategic alliance for the development and commercialization of Prochymal and Chondrogen. Under the terms of the agreement, Osiris retains commercialization rights to Prochymal and Chondrogen in the United States and Canada. Genzyme holds these rights in all other countries except Japan, where JCR Pharmaceuticals holds rights to Prochymal for the treatment of patients with hematological malignancies.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include statements about our expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as "anticipate," "believe," "continue," "ongoing," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project" or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Examples of forward-looking statements include, but are not limited to, statements regarding the following: our product development efforts; our clinical trials and anticipated regulatory requirements and the ability to successfully navigate these requirements; the success of our product candidates in development; status of the regulatory process for our biologic drug candidates; implementation of our corporate strategy; our financial performance; our product research and development activities and projected expenditures, including our anticipated timeline and clinical strategy for Prochymal, Chondrogen and our other MSC and biologic drug candidates; our cash needs; patents and proprietary rights; the safety and ability of our potential products to treat disease and the results of our scientific research; our plans for sales and marketing; our plans regarding our facilities; types of regulatory frameworks we expect will be applicable to our potential products; and results of our scientific research. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Risks and uncertainties related to our Collaboration Agreement with Genzyme for the development and commercialization of Prochymal and Chondrogen include, among others: typical business transactional risks; risks related to product development and clinical trial design, performance and completion; uncertainty of the success of Prochymal and Chondrogen in clinical trials and their ability to treat disease; Genzyme’s early termination and opt-out rights; the ability of Osiris and Genzyme to successfully navigate regulatory requirements and to manufacture and commercialize products; and the uncertainty as to our ability to successfully perform under the collaborative arrangement and earn milestone and royalty payments thereunder. Our actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors described in the section entitled "Risk Factors" in our Annual Report on Form 10-K and other Periodic Reports filed on Form 10-Q, with the United States Securities and Exchange Commission. Accordingly, you should not unduly rely on these forward-looking statements. We undertake no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this press release or to reflect the occurrence of unanticipated events.